HSCS - Heart Test Labs Long-Term Liabilities to Capital

Serving as a valuation tool, the Heart Test Laboratories (HSCS) price chart demonstrates long-term debt amounting to 0.00. Heart Test Laboratories is integrating AI into cardiac screening, replacing costly ultrasound with MyoVista rapid analysis. Management aims to scale device sales by expanding insurance reimbursements and securing regulatory approvals. Seeking new niches in primary care clinics helps the company bypass the saturated market for standard electrocardiographs.

This indicator reflects the financial stability of the business through the balance of debt and equity. The formula compares liabilities with a maturity of over one year against shareholders' equity to assess the debt load. Analyzing the ratio of long-term credit funds to equity helps identify insolvency risks or the underutilization of financial leverage. Reducing this coefficient is critically important for Heart Test Laboratories (HSCS) while awaiting FDA certification. Stable capital will ensure the development of the MyoVista ecosystem without excessive pressure from creditors.